European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration Associated.

Slides:

Advertisements

Similar presentations

Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M.

Advertisements

The Diabetic Retinopathy Clinical Research Network One-Year Results from a Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for.

The Diabetic Retinopathy Clinical Research Network

AMD Trials and Treatments:

A Comparison between Fluorescein Angiography and Optical Coherence Tomography Findings in Patients with Clinically Significant Macular Edema KoriAnne Elkins.

YAG capsulotomy K.P.SHANTHA SORUBARANI.

Risk Factors for RVO and CRVO

Grand Rounds Peripheral Exudative Hemorrhagic Chorioretinopathy

Anti VEGF Options in the management of CNV 1)Observation  occult CNV also requires close follow – up.every 3 month 2) Laser coagulation 3) Surgery.

World Cornea Congress VII – Electronic Poster Season Tse Wing Yeung, MBBS, FRANZCO Ronan Conlon, MD; Joshua Teichman, MD, FRCSC; Setareh Ziai, MD, FRCSC;

Optical Coherence tomography Imaging of Spontaneous closure of Psuedophakic full thickness macular hole, 8 months post operative Dr. Jenin Patel Lotus.

Vitrectomy Outcomes in Eyes with Diabetic Macular Edema, Visual Loss, and Vitreomacular Traction Sponsored by the National Eye Institute, National Institutes.

Anupama Kotha 1, Simar J. Singh 1, William B. Trattler 1,2, Carlos Buznego 1,2 The authors have no financial interest in the subject matter of this poster.

Boston Type I Keratoprosthesis and Silicone Oil for the Treatment of Hypotony in Prephthisis Kristiana D. Neff 1, William I. Sawyer 2, Michael R. Petersen.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Aref.

Panel Questions 1.Please discuss the following regarding endothelial cell density: a.The primary safety endpoint for this study was mean ECD ≤ 17%. The.

The Diabetic Retinopathy Clinical Research Network

Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment for Diabetic Macular Edema Sponsored by the National Eye Institute,

1 Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) Jaffe GJ, Martin DF, Toth CA, Daniel.

Mahmood J Showail 11/03/2009. A 17 -year-old high school female student presented to our clinic with history of sudden decrease of vision in her left.

The Diabetic Retinopathy Clinical Research Network

Luu CD, Dimitrov PN, Robman L, et al. Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. Arch Ophthalmol. 2012;130(6):

Hayashi Eye Hospital, Fukuoka, Japan

TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia Dr.Muhammad Hamza North Devon District NHS Hospital NICE.

Laser-Ranibizumab-Triamcinolone for DME Study DRCR.net Protocol I

Retinal nerve fiber layer thickness change in patients with wet AMD treated with ranibizumab, short term results Advantages: To determine the effect of.

Gene Transfer for Neovascular Age- Related Macular Degeneration Peter A. Campochiaro The Wilmer Eye Institute The Johns Hopkins University School of Medicine.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: VEGFA and VEGFR1 and Response to Anti-VEGF Hagstrom SA, Ying G, Pauer GJT, et.

Phase IIIb Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration PIER Study Year 1 Regillo CD,

Assessment of macular thickness and function by optical coherence tomography and multifocal electroretinogram in uncomplicated cataract surgery Yang Li,

A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study.

The Diabetic Retinopathy Clinical Research Network What is the Role of Laser In Treating Diabetic Macular Edema in the Era of Anti-VEGF Therapy? 1.

OCT in Amblyopia Lionel Kowal.

The Diabetic Retinopathy Clinical Research Network

Results of Collagen Crosslinking followed by posterior chamber toric implantable collamer lens implantation in patients with Keratoconus & High Myopia.

Visual acuity gain after cataract surgery improves the balance and gait parameters Sinan Emre 1, Bekir Durmus 2, Özlem Baysal 2 1 Celal Bayar University,

Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema (DME) Part 2 A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education.

REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject.

Alexander J. Brucker, M.D. Protocol Chair

J. Brian Foster, MD No Financial Disclosures

Adriana S. Forseto1, MD Walton Nosé1,2, MD

Nang-Hee Song(MD) 1, Jae-Woong Koh (MD/PhD) 1, Gil-Joong Yoon (MD/PhD) 2 Department of Ophthalmology, Chosun University College of Medicine, Gwangju, Republic.

Surgical Therapy of CME Non-responsive to Medical Therapy Henry J Kaplan, MD Evans Professor of Ophthalmology Chair, Ophthalmology & Visual Sciences Director,

Sponsored by the National Eye Institute,

Chronic Visual Loss. CHRONIC VISUAL LOSS 1. Measure intraocular pressure with a tonometer 2. Evaluate the nerve head 3. Evaluate the clarity of the lens.

Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health.

The Diabetic Retinopathy Clinical Research Network DRCR.net Prompt PRP vs Ranibizumab+Deferred PRP for PDR Study Jeffrey G. Gross, M.D. – Protocol Chair.

Live intraocular worm causing multifocal choroiditis Dr Mamta Agarwal Dr J Biswas.

COMPARATIVE EFFICACY OF INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR OEDEMA J.A. Montero, J.M. Ruiz-Moreno VISSUM, Alicante.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Single-Nucleotide Polymorphisms and Age-Related Macular Degeneration Maguire MG,

BRVO. Present by Sattar Heidari MD General ophthalmologist.

THE EBK PROCEDURE FOR CORRECTION OF REFRACTIVE ERRORS

The Diabetic Retinopathy Clinical Research Network

The Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year.

A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice Ophthalmologica 2011;225:112–119.

Outer Retinal Tubulation

Correlation between visual acuity

Correlation between Deep Capillary Plexus Perfusion and Long-Term Photoreceptor Recovery after Diabetic Macular Edema Treatment Byung Gil Moon, MD, Taewoong.

가톨릭대학교 의과대학 안과 및 시과학 교실 R3 장동진 / Pf.이원기

The Diabetic Retinopathy Clinical Research Network

Volume 123, Issue 6, Pages (June 2016)

Retina Centre of Ottawa Clinical Trials

Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration Ursula Schmidt-Erfurth,

Crosslinking with Simultaneous Implantation of Intrastromal Corneal Ring Segments in Keratoconus: Safe and Efficacy Author: Luiz Antonio de Brito Martins.

Randomized Clinical Trial Jeffrey G. Gross, M.D. for the DRCR Network

J. Fernando Arevalo, MD FACS Clínica Oftalmológica Centro Caracas

The Diabetic Retinopathy Clinical Research Network

Presentation transcript:

European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration Associated With Retinal Pigment Epithelial Detachment

Financial Disclosure  Dr Olesya Ziyatdinova (the presenter) has no financial interest in the subject matter of this topic

Purpose To evaluate the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment. Materials and methods The study included 15 patients (15 eyes) with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.

5 eyes with foveal involvement 10 eyes without foveal involvement

 Duration of disease: from 3 to 12 months  Observation time: 12 months  Number of injections: from 1 to 6 times

Technique  Injection of 0,5 mg (0,05ml) of ranibizumab into vitreous body  Lower quadrant at a distance of 4 mm from limbus, needle 30G  Slow introduction  IOP control and instillation of antibiotics after operation

Technique

Criteria of efficacy Visual acuity (BCVA, UCVA) Ophthalmoscopy OCT

Results Average BCVA increased from 20/100 to 20/50 and the average retinal thickness decreased from 367 +/-111 mkm to 281+/- 104 mkm in 8 eyes (53,4%) without foveal involvement.

BCVA remained stable in 5 eyes (33,3%) but there was a decrease only in 2 eyes (13,3%) with foveal involvement. 3 eyes (20%) showed disease stabilization after 1 st injection 12 eyes (80%) required re-injection of the ranibizumab for 1-2 months Results

Before 1 month later 3 months later OCT dynamics

Conclusions  Intravitreal ranibizumab was effective in improving or stabilizing vision of patients with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.  The functional results were better in eyes without foveal involvement with retinal pigment epithelial detachment.  Visual acuity and OCT data are reliable criteria for evaluating the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.